» Articles » PMID: 24984745

Bone Marrow Cell Transplantation Time-dependently Abolishes Efficacy of Granulocyte Colony-stimulating Factor After Stroke in Hypertensive Rats

Overview
Journal Stroke
Date 2014 Jul 3
PMID 24984745
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: We aimed to determine a possible synergistic effect of granulocyte colony-stimulating factor (G-CSF) and bone marrow-derived mononuclear cells (BM MNC) after stroke in spontaneously hypertensive rats.

Methods: Male spontaneously hypertensive rats were subjected to middle cerebral artery occlusion and randomly assigned to daily injection of 50 μg/kg G-CSF for 5 days starting 1 hour after stroke (groups 1, 2, and 3) with additional intravenous transplantation of 1.5×10E7 BM MNC per kilogram at 6 hours (group 2) or 48 hours (group 3) after stroke, or control treatment (group 4). Circulating leukocyte counts and functional deficits, infarct volume, and brain edema were repeatedly assessed in the first week and first month.

Results: G-CSF treatment led to a significant neutrophilia, to a reversal of postischemic depression of circulating leukocytes, and to a significantly improved functional recovery without affecting the infarct volume or brain edema. BM MNC cotransplantation was neutral after 6 hours, but reversed the functional effect of G-CSF after 48 hours. Short-term investigation of combined G-CSF and BM MNC treatment at 48 hours indicated splenic accumulation of granulocytes and transplanted cells, accompanied by a significant rise of granulocytes in the circulation and the ischemic brain.

Conclusions: G-CSF improved functional recovery in spontaneously hypertensive rats, but this effect was abolished by cotransplantation of BM MNC after 48 hours. In the spleen, transplanted cells may hinder the clearance of granulocytes that were massively increased by G-CSF. Increased circulation and infiltration of granulocytes into the ischemic brain may be detrimental for stroke outcome.

Citing Articles

Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research.

Laso-Garcia F, Diekhorst L, Gomez-de Frutos M, Otero-Ortega L, Fuentes B, Ruiz-Ares G Front Neurol. 2019; 10:332.

PMID: 31024426 PMC: 6467162. DOI: 10.3389/fneur.2019.00332.


Future of Animal Modeling for Poststroke Tissue Repair.

Modo M, Jolkkonen J, Zille M, Boltze J Stroke. 2018; 49(5):1099-1106.

PMID: 29669872 PMC: 6013070. DOI: 10.1161/STROKEAHA.117.018293.


Bone Marrow Stromal Cells Combined With Sodium Ferulate and -Butylidenephthalide Promote the Effect of Therapeutic Angiogenesis via Advancing Astrocyte-Derived Trophic Factors After Ischemic Stroke.

Zhang Q, Chen Z, Zhao Y, Liu B, Liu N, Ke C Cell Transplant. 2016; 26(2):229-242.

PMID: 27772541 PMC: 5657770. DOI: 10.3727/096368916X693536.


Is Immunomodulation a Principal Mechanism Underlying How Cell-Based Therapies Enhance Stroke Recovery?.

Satani N, Savitz S Neurotherapeutics. 2016; 13(4):775-782.

PMID: 27485235 PMC: 5081125. DOI: 10.1007/s13311-016-0468-9.


Recurrent mild cerebral ischemia: enhanced brain injury following acute compared to subacute recurrence in the rat.

Tuor U, Zhao Z, Barber P, Qiao M BMC Neurosci. 2016; 17(1):28.

PMID: 27230275 PMC: 4881167. DOI: 10.1186/s12868-016-0263-x.